文献速递胃肠动力与功能性疾病消化内镜

胃经口内镜下幽门肌切开术治疗胃轻瘫的长期结局

Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-05-22

该单中心回顾性病例系列纳入90例难治性胃轻瘫患者,评估胃经口内镜下幽门肌切开术(GPOEM)的长期疗效。初次随访时81.1%患者有临床应答,1年时69.1%全部患者仍有应答,85.2%初始应答者维持应答。较长病程和高BMI与GPOEM失败相关。

要点

  • GPOEM术后初次随访81.1%难治性胃轻瘫患者有临床应答。
  • 1年时69.1%全部患者有临床应答,85.2%初始应答者维持应答。
  • 较长病程和高BMI与GPOEM失败相关。

核心结论

  • GPOEM治疗难治性胃轻瘫在初次随访时81.1%患者有临床应答,疗效可维持至术后3年。
  • 较长病程和高BMI与GPOEM失败相关。

研究设计与样本

  • 单中心回顾性病例系列研究,2015年6月至2019年3月共97例接受GPOEM的难治性胃轻瘫患者,90例有超过3个月随访数据纳入最终分析。

主要发现

  • 初次随访(术后3至6个月)73例(81.1%)有临床应答且SF-36评分显著升高,17例(18.9%)无应答。
  • 术后6个月7.1%复发,12个月8.3%复发,24个月4.8%复发,36个月14.3%复发。
  • 初始临床应答者每年应答丢失率为12.9%。

关键数值与推荐

  • 临床应答定义:平均总GCSI评分下降至少1分且至少2个核心症状子量表下降超过25%。
  • 复发定义:初始完全应答后GCSI恢复至基线或GCSI评分≥3持续至少2个月。
  • GPOEM失败定义:无应答或6个月内胃轻瘫复发。

临床怎么用

  • GPOEM可用于难治性胃轻瘫,但较长病程和高BMI患者应答可能性较低,决策时应考虑这些因素。

局限性

  • 回顾性单中心病例系列设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gastric per oral endoscopic pyloromyotomy (GPOEM) is a promising treatment for gastroparesis. There are few data on the long-term outcomes of this procedure. We investigated long-term outcomes of GPOEM treatment of patients with refractory gastroparesis. METHODS: We conducted a retrospective case-series study of all patients who underwent GPOEM for refractory gastroparesis at a single center (n = 97), from June 2015 through March 2019; 90 patients had more than 3 months follow-up data and were included in our final analysis. We collected data on gastroparesis cardinal symptom index (GCSI) scores (measurements of postprandial fullness or early satiety, nausea and vomiting, and bloating) and SF-36 questionnaire scores (measures quality of life). The primary outcome was clinical response to GPOEM, defined as a decrease of at least 1 point in the average total GCSI score with more than a 25% decrease in at least 2 subscales of cardinal symptoms. Recurrence was defined as a return to baseline GCSI or GCSI scores of 3 or more for at least 2 months after an initial complete response. The secondary outcome was the factors that predict GPOEM failure (no response or gastroparesis recurrence within 6 months). RESULTS: At initial follow-up (3 to 6 months after GPOEM), 73 patients (81.1%) had a clinical response and significant increases in SF-36 questionnaire scores (indicating increased quality of life) whereas 17 patients (18.9%) had no response. Six months after GPOEM, 7.1% had recurrence. At 12 months, 8.3% of patients remaining in the study had recurrence. At 24 months, 4.8% of patients remaining in the study had a recurrence. At 36 months, 14.3% of patients remaining in the study had recurrence. For patients who experienced an initial clinical response, the rate of loss of that response per year was 12.9%. In the univariate and multivariate regression analysis, a longer duration of gastroparesis reduced the odds of response to GPOEM (odds ratio [OR], 0.092; 95% CI, 1.04-1.3; P = .001). On multivariate logistic regression, patients with high BMIs had increased odds of GPOEM failure (OR, 1.097; 95% CI, 1.022-1.176; P = .010) and patients receiving psychiatric medications had a higher risk of GPOEM failure (OR, 1.33; 95% CI, 0.110-1.008; P = .052). CONCLUSIONS: In retrospective analysis of 90 patients who underwent GPOEM for refractory gastroparesis, 81.1% had a clinical response at initial follow-up of their procedure. 1 year after GPOEM, 69.1% of all patients had a clinical response and 85.2% of initial responders maintained a clinical response. Patients maintained a clinical response and improved quality of life for as long as 3 years after the procedure. High BMI and long duration gastroparesis were associated with failure of GPOEM.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Abdelfatah MM, Noll A, Kapil N, et al. Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis. Clin Gastroenterol Hepatol. 2020. PMID: 32450364. doi:10.1016/j.cgh.2020.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。